BPC-157 Dosage: Injection vs. Oral, Cycles & Units
Content
Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
BPC-157 dosing is not FDA-approved. Most protocols use 250–500 mcg daily by injection or 500 mcg–1 mg orally, adjusted for condition, route, and body weight.
Precision matters because BPC-157 has no official prescribing guidelines. Dosing information comes from animal studies, practitioner experience, and anecdotal reports.
Route affects dose. Subcutaneous injections offer about 75–95% bioavailability. Oral dosing usually needs 1.5–2 times more due to lower absorption.
Accurate measurement and reconstitution are critical. Confusing mg with mcg creates a 1,000x dosing error. Cycles usually last 4–12 weeks, followed by similar-length breaks.
BPC-157 is a synthetic 15-amino-acid peptide first described in 1993, with its sequence derived from a protein found in human gastric juice. In preclinical models, it has been associated with angiogenesis, collagen synthesis, fibroblast activity, and reduced inflammatory cytokine activity.1 These promising effects have driven interest in human use. Because BPC-157 is not FDA-approved for any human indication, no official prescribing label exists. There is no package insert, black-box warning, or FDA-reviewed dosing table.
Clinicians and patients rely on animal research, practitioner experience, and anecdotal reports, which creates confusion for anyone trying to use BPC-157 responsibly. This guide offers a clear, practical, safety-focused framework that covers typical dose ranges, measurement math, route comparisons, and cycle logistics. It is educational only, and professional medical supervision is strongly recommended before starting any peptide protocol.
Many patients want to know how many units to draw on an insulin syringe. The answer depends entirely on how the vial is reconstituted. The core conversion to remember is simple: 1 mg = 1,000 mcg. Vials are labeled in mg, while doses are prescribed in mcg.
Here is a step-by-step reconstitution example using a standard 5 mg vial:
Start with a 5 mg vial of lyophilized BPC-157.
Add 2 mL of bacteriostatic water, injecting it slowly down the vial wall.
The resulting concentration is 2,500 mcg/mL (2.5 mg/mL).
A 250 mcg dose equals 0.1 mL, which is 10 units on a U-100 insulin syringe.
A 500 mcg dose equals 0.2 mL, which is 20 units.
Once you have reconstituted your 5 mg vial with 2 mL of water, use this quick-reference list to find the unit mark for your target dose without recalculating each time:
Critical Warning:Confusing mg with mcg is a 1,000x error. Always double-check your math before drawing a dose. If your vial size or water volume differs from the example above, recalculate your concentration before proceeding.
Doctor’s Take — Dr. Akash Chandawarkar, MD: At Mirror Plastic Surgery, no two peptide protocols are identical. Every BPC-157 plan is designed around the individual’s baseline labs, medical history, specific injury or condition, and personal goals. Oversight from a board-certified physician separates a protocol that works from one that wastes time and money or causes harm. The dose is only one variable; the source, cycle structure, and monitoring framework matter just as much.
Mirror Plastic Surgery’s approach to BPC-157 focuses on safety and personalization:
In-depth consultation with Dr. Akash Chandawarkar, a Harvard-educated, Johns Hopkins-trained, board-certified plastic surgeon
Baseline lab panels, including liver, kidney, thyroid, and metabolic markers, to screen for safety and establish reference points
Peptides sourced from reputable providers with batch testing and Certificates of Analysis
Personalized protocols based on individual physiology, labs, and goals
Ongoing concierge support via text or telemedicine throughout the protocol
Arrange a peptide consultation with Ellie at Mirror Plastic Surgery to explore how a tailored, medically supervised protocol can support your recovery and wellness goals.
Myth 2: “BPC-157 is only for bodybuilders.” BPC-157 is studied across a wide range of applications, including gut health, post-surgical recovery, systemic inflammation, and interstitial cystitis.
Myth 4: “You can trust any online vendor.” As noted in the safety section, a significant portion of online peptides fail quality testing, with 30% showing incorrect sequences and 65% exceeding endotoxin limits. Quality varies dramatically across unregulated commercial sources.
Frequently Asked Questions
How Many Units Of BPC-157 Should I Take?
The number of units depends entirely on how you reconstitute the vial. Units are not a fixed measure of dose; they reflect a volume drawn on a specific syringe type. For a 5 mg vial reconstituted with 2 mL of bacteriostatic water, the concentration is 2,500 mcg/mL. On a standard U-100 (1 mL, 100-unit) insulin syringe, a 250 mcg dose equals 10 units and a 500 mcg dose equals 20 units. If you use a different vial size or add a different volume of water, recalculate your concentration before drawing. Using a 0.5 mL or 0.3 mL syringe improves precision for small doses.
Can I Take BPC-157 Orally?
Yes. Oral BPC-157 is a viable option, particularly for gastrointestinal conditions, because the peptide is unusually stable in stomach acid compared to most peptides. However, oral bioavailability is lower and more variable than subcutaneous injection, so oral doses are typically higher, usually 500 mcg to 1 mg once or twice daily. For musculoskeletal injuries, injectable administration is generally preferred because it delivers higher systemic concentrations and allows localized injection near the injury site. Some practitioners use both routes simultaneously when a patient has concurrent gut and musculoskeletal issues.
How Long Does A BPC-157 Cycle Last?
Typical cycles run 4–12 weeks depending on the condition. Acute soft-tissue injuries often respond within 4–6 weeks. Chronic tendinopathy or joint issues generally require 6–8 weeks. Post-surgical recovery protocols commonly run 8–12 weeks. Gut healing protocols using oral BPC-157 typically last 6–8 weeks. A break of at least 4–6 weeks, or roughly equal to the cycle length, is recommended between cycles to allow reassessment and preserve receptor sensitivity. No taper is required when stopping, as BPC-157 does not suppress an endocrine axis.
What Are The Side Effects Of BPC-157?
Most reported side effects are mild. Injection site reactions, including redness, slight swelling, and localized warmth, are the most common and typically resolve within a few hours. Temporary nausea is more common with oral dosing. Headache and dizziness are uncommon. A theoretical concern exists around BPC-157’s angiogenic properties and their potential relevance to tumor growth, though no direct carcinogenic effect has been demonstrated in animal studies. Individuals with active cancer, a history of cancer, pregnancy, breastfeeding, or hepatic impairment should avoid BPC-157. Long-term safety data in humans is lacking, which is why medical supervision, baseline labs, and cycling protocols are strongly advised.
Published data on drug interactions with BPC-157 is extremely limited. Disclose all medications, supplements, and health conditions to your physician before starting any peptide protocol. BPC-157 should be avoided during pregnancy, breastfeeding, and by individuals with active or recent cancer. Because it promotes angiogenesis, those on blood thinners or with clotting disorders should exercise particular caution and consult their physician. A comprehensive medication review is a standard part of the consultation process at Mirror Plastic Surgery.
The Bottom Line On BPC-157 Dosage
There is no FDA-approved standard dose for BPC-157. Typical injectable protocols use 250–500 mcg daily, extrapolated from animal research using allometric scaling. Oral doses are higher, usually 500 mcg to 1 mg daily, to compensate for lower bioavailability. Cycles run 4–12 weeks depending on the condition, followed by breaks of roughly equal length. Weight-based dosing of 2–4 mcg/kg daily offers a rational starting framework for injections, but injury severity and chronicity usually drive final dose selection.
The most important decisions involve more than the dose. Source quality and medical supervision strongly influence both safety and results. Unregulated online peptides carry documented risks of incorrect amino acid sequences, low peptide content, and dangerous endotoxin levels. A medically supervised protocol with baseline labs, quality-assured peptides, and ongoing monitoring provides a framework that addresses both efficacy and safety.
This article is for educational purposes and does not replace medical advice. Peptides are not FDA-approved for general use, and results vary. Always consult a qualified healthcare provider before starting any peptide therapy.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
